News Conference News ACC 2024 TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP L.A. McKeown April 16, 2024
News Conference News ACC 2024 Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing Michael O'Riordan April 12, 2024
News Conference News ACC 2023 CRP More Predictive of Future Events Than LDL in Statin-Treated Patients Caitlin E. Cox March 14, 2023
News Conference News ACC 2023 Oral PCSK9 Inhibitor Reduces LDL Cholesterol in Phase IIb Study Todd Neale March 10, 2023
News Conference News ACC 2023 NUDGE-FLU: Emails May Help Increase Flu Vaccination in Elderly L.A. McKeown March 05, 2023
News Conference News ACC 2022 SPYRAL HTN-ON MED at 3 Years: Renal Denervation’s BP Impact Endures Todd Neale April 08, 2022
News Conference News ACC 2022 Modest Effects, Safety Concerns Plague Vupanorsen in TRANSLATE-TIMI 70 Michael O'Riordan April 07, 2022
News Conference News ACC 2022 What’s Going to Be Hot at ACC 2022, In Person or Virtual Shelley Wood March 28, 2022
News Conference News ACC 2021 High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE Michael O'Riordan May 15, 2021
News Conference News ACC 2019 Sonothrombolysis for Acute STEMI? High-Frequency Microbubbles Show Promise in MRUSMI L.A. McKeown March 27, 2019
News Conference News ACC 2018 Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues Michael O'Riordan March 11, 2018
News Conference News ACC 2018 ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last Shelley Wood March 05, 2018
News Conference News ACC 2017 ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience Michael O'Riordan March 18, 2017
News Conference News ACC 2017 CARAT: Novel HDL Mimetic Fails to Show Benefit in Coronary Atherosclerosis After ACS Yael L. Maxwell March 18, 2017
News Conference News ACC 2017 ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s Yael L. Maxwell March 17, 2017